ADMA — ADMA BIOLOGICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1368514 ·
Last close
$13.63
Market Cap
$3.02B
52W High
$20.46
52W Low
$7.21
ADV30
3,751,158
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 141,102,000 | 99,917,000 | 67,757,000 | 49,884,000 | 732,485,000 | 124,555,000 | 293,978,000 |
| Jun 2026 | 124,395,000 | 86,277,000 | 52,445,000 | 37,822,000 | 684,210,000 | 136,020,000 | 276,002,000 |
| Mar 2026 | 114,493,000 | 80,750,000 | 50,294,000 | 45,328,000 | 665,184,000 | 138,153,000 | 274,859,000 |
| Dec 2025 | 139,163,000 | 88,816,000 | 62,751,000 | 49,379,000 | 624,242,000 | 87,630,000 | 146,922,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$140,795,000
Investing CF
$-2,196,000
Financing CF
$-75,429,000
CapEx
$-8,196,000
Dividends Paid
—
Buybacks
$-189,202,000
EPS Diluted TTM
$0.77
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-28,619,000
Inventory
$266,115,000
Receivables
$169,223,000
ST Investments
—
EBIT TTM
$245,145,000
Pretax Income TTM
$234,563,000
Interest Exp TTM
$10,582,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$519,152,992
EBITDA
$240,702,000
Free Cash Flow
$90,261,624
Enterprise Value
$2,902,455,296
Total Cash
$124,555,000
Total Debt
$202,804,000
Shares Out
221,854,389
Trailing EPS
$0.77
Book Value
$1.97
ROE
41.9%
ROA
22.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 510,173,000 | 191,443,000 | 146,930,000 | 624,242,000 | 146,922,000 | 477,320,000 | 50,396,000 |
| Dec 2024 | 426,454,000 | 138,983,000 | 197,673,000 | 488,678,000 | 139,660,000 | 349,018,000 | 118,672,000 |
| Dec 2023 | 258,215,000 | 21,632,000 | -28,239,000 | 329,182,000 | 193,976,000 | 135,206,000 | 8,800,000 |
| Dec 2022 | 154,080,000 | -39,365,000 | -65,904,000 | 348,461,000 | 196,487,000 | 151,974,000 | -59,508,000 |
TTM Snapshot
Revenues TTM
$512,275,000
NetIncome TTM
$168,957,000
OpCashFlow TTM
—
Assets (Latest)
$684,210,000
Forward EPS
$1.01
Max Pain — expiry 2027-01-15
max pain strike: $13.00 · spot: $13.56 · call oi: 13,262 · put oi: 2,024Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VCEL | Vericel Corp | $2.95B | $57.88 | — |
| DNLI | Denali Therapeutics Inc. | $2.89B | $18.00 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $3.48B | $7.53 | — |
| RLAY | Relay Therapeutics, Inc. | $3.64B | $16.47 | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.86B | $78.20 | — |
News headlines (Yahoo Finance, 1h cache)
ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?
2026-11-11 16:41 · Yahoo
Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average
2026-11-06 13:35 · Yahoo
Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average
2026-11-06 13:30 · Yahoo
Q3 Earnings Beat Might Change The Case For ADMA Biologics Stock
2026-11-06 10:12 · Yahoo
ADMA Biologics (ADMA) Q3 2026 Earnings Call Transcript
2026-11-05 18:13 · Yahoo
ADMA Biologics Inc (ADMA) Q3 2026 Earnings Call Highlights: Asceniv Surge Drives Margin ...
2026-11-05 17:08 · Yahoo
Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates
2026-11-04 23:45 · Yahoo
ADMA Biologics Q3 Earnings Call Highlights
2026-11-04 23:14 · Yahoo
Adma Biologics: Q3 Earnings Snapshot
2026-11-04 22:41 · Yahoo
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-04 21:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.